Drugs / clobetasol propionate
clobetasol propionate
also known as
Dermovate · Clobex · clobetasol · Dermoval · Olux-E · Clobederm · Clobetasol 17-propionate · Clobex Shampoo · +6 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | OLUX | — | 2002-12-20 | fda.gov ↗ |
| Label expansion | US (FDA) | TEMOVATE E | — | 1996-05-03 | fda.gov ↗ |
| Approved | US (FDA) | TEMOVATE | — | 1985-12-27 | fda.gov ↗ |
Trials 40
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02973776 | Dec 2016 → Feb 2017 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02355639 | Jan → Apr 2015 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01946386 | Sep → Oct 2013 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01381445 | Apr → Jul 2011 | atopic eczema | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01043224 | Jan → Mar 2010 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00864240 | Oct 2005 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03847389 | Sep 2019 → May 2020 | atopic eczema | Hill Dermaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 28 trials · 1 met primary | ||||||
| Phase 2 | NCT07812701 | Sep → Nov 2026 expected | osteoarthritis, hand | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07100613 | Sep 2024 → Oct 2027 expected | lichen planus, oral, mouth mucosa disorder | University of Palermo | Recruiting | No outcome recorded |
| Phase 2 | NCT06363539 | Sep 2022 → Mar 2023 | pyogenic granuloma | Children Hospital and Institute of Child Health, Lahore | Completed | No outcome recorded |
| Phase 2 | NCT04089735 | Aug 2019 → Apr 2020 | — | Formosa Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03592342 | Jun 2018 → Dec 2019 | lichen planus, oral | Dermtreat | Completed | No outcome recorded |
| Phase 2 | NCT02368886 | Mar 2015 → Sep 2017 | colon adenocarcinoma, rectum adenocarcinoma | Academic and Community Cancer Research United | Completed | Met primary |
| Phase 2 | NCT02131324 | May 2014 → Apr 2016 | psoriasis | Promius Pharma, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01567215 | May 2012 → Feb 2014 | — | Pernille Pedersen | Completed | No outcome recorded |
| Phase 310 trials · 5 met primary | ||||||
| Phase 3 | NCT05724446 | Dec 2022 → Dec 2025 overdue | cataract | Salvat | Recruiting | No outcome recorded |
| Phase 3 | NCT05364515 | Dec 2021 → Feb 2024 | vulvar lichen sclerosus | Fundación Eduardo Anitua | Withdrawn | No outcome recorded |
| Phase 3 | NCT04246801 | Jun 2020 → May 2021 | cataract | Salvat | Completed | No outcome recorded |
| Phase 3 | NCT04249076 | Jun 2020 → Apr 2021 | cataract | Salvat | Completed | No outcome recorded |
| Phase 3 | NCT02573883 | Oct 2015 → Sep 2019 | vulvar lichen sclerosus | Medstar Health Research Institute | Completed | Met primary |
| Phase 3 | NCT01235442 | Sep 2010 → Oct 2011 | psoriasis | Amgen | Completed | Met primary |
| Phase 3 | NCT00862654 | Mar 2009 → Feb 2010 | seborrheic dermatitis | Galderma R&D | Completed | Met primary |
| Phase 3 | NCT02313870 | Jan 2008 → May 2015 | bullous pemphigoid | University Hospital, Montpellier | Completed | Met primary |
| Phase 3 | NCT00400725 | Sep 2006 → Aug 2007 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT01453686 | Aug 2002 → Aug 2003 | alopecia areata | The Hospital for Sick Children | Completed | Met primary |
| Phase 410 trials | ||||||
| Phase 4 | NCT03926377 | Dec 2020 → Oct 2025 | bullous pemphigoid, osteoporosis | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 4 | NCT02733874 | Apr 2015 → Apr 2016 | psoriasis | First Hospital of China Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02360202 | Feb 2015 → Feb 2017 | bullous pemphigoid | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 4 | NCT01893567 | Jul → Oct 2013 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT01012713 | Jun 2010 → Dec 2014 | psoriasis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT01111981 | Oct 2009 → Feb 2010 | alopecia | Callender Center for Clinical Research | Unknown | No outcome recorded |
| Phase 4 | NCT00988637 | Oct 2009 → Mar 2010 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00852761 | Mar → Jun 2009 | psoriasis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00828464 | Oct 2008 → Jan 2009 | hand dermatosis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00842153 | Nov → Dec 2007 | psoriasis | Stiefel, a GSK Company | Completed | Mixed |
| Phase not applicable5 trials | ||||||
| — | NCT07278999 | Dec 2025 → Oct 2026 expected | lichen planus, oral, multiple mucosal neuroma | Medical University of Silesia | Recruiting | No outcome recorded |
| — | NCT07641725 | Nov 2025 → Sep 2026 overdue | pemphigus vulgaris | Damascus University | Recruiting | No outcome recorded |
| — | NCT06856590 | Feb → Sep 2025 | hand-foot syndrome | Gazi University | Completed | No outcome recorded |
| — | NCT03779360 | Oct 2018 → Feb 2019 | dermatitis | Centre for Human Drug Research, Netherlands | Completed | No outcome recorded |
| — | NCT02492373 | Feb 2015 → May 2016 | hyperpigmentation of the skin, lentigo | Mahidol University | Completed | No outcome recorded |
| Comparator or background therapy42 trials | ||||||
| Phase 0 | NCT07398807 Comparator | Aug 2025 → Feb 2026 overdue | vitiligo | Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan | Recruiting | No outcome recorded |
| Phase 0 | NCT06555497 Comparator | Jan 2022 → Dec 2023 | psoriasis | Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium | Completed | No outcome recorded |
| Phase 1 | NCT05885269 Comparator | Nov 2022 → Apr 2023 | alopecia areata | Combined Military Hospital Abbottabad | Completed | No outcome recorded |
| Phase 1 | NCT03878771 Comparator | Mar → Apr 2019 | Stevens-Johnson syndrome, mucous membrane pemphigoid, pemphigus vulgaris | Beni-Suef University | Completed | No outcome recorded |
| Phase 1 | NCT03758365 Comparator | Nov 2018 | vascular disorder | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02936492 Comparator | Oct 2016 → Apr 2017 | psoriasis | Bayer | Terminated | No outcome recorded |
| Phase 1 | NCT02940002 Comparator | Oct 2016 → Jan 2017 | psoriasis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02392130 Comparator | Mar → Jun 2015 | connective tissue disorder, skin disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02376049 Comparator | Feb → Jul 2015 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT05706870 Comparator | Dec 2022 → Jan 2024 | psoriasis | GEN İlaç ve Sağlık Ürünleri A.Ş. | Completed | Met primary |
| Phase 2 | NCT03386643 Comparator | Nov 2017 → Apr 2018 | lichen planus, oral | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2 | NCT03026478 Comparator | May 2016 → Mar 2018 | lichen planus, oral | Garlapati Komali | Unknown | No outcome recorded |
| Phase 2 | NCT01126255 Comparator | Mar 2011 → Jul 2014 | vulvar lichen sclerosus | Insel Gruppe AG, University Hospital Bern | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT00757874 Comparator | Apr 2006 → Nov 2009 | vulvar lichen sclerosus | Deana Funaro | Completed | No outcome recorded |
| Phase 2/3 | NCT05243563 Background | Apr 2022 → Jun 2024 | vulvar lichen sclerosus | University of South Alabama | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT04364555 Comparator | May 2020 → Jul 2024 overdue | lichen planus, oral | Malmö University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01282515 Comparator | Aug 2011 → Oct 2014 | lichen planus | Oslo University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04649697 Comparator | Dec 2020 → Dec 2023 | rheumatoid arthritis | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT00658788 Comparator | Mar 2008 → Jan 2009 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00438399 Comparator | Feb 2007 → Jan 2008 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT07666620 Comparator | Oct 2026 → Apr 2027 expected | hypertrophic lichen planus | Noor Aziz | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06042647 Comparator | Jul → Nov 2023 | psoriasis | Dermatology Consulting Services, PLLC | Completed | No outcome recorded |
| Phase 4 | NCT04951206 Comparator | Mar 2022 → Apr 2025 | vulvar lichen sclerosus | Medstar Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03535233 Comparator | Mar 2016 → Jun 2017 | alopecia areata | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02487212 Comparator | Apr 2014 → Apr 2015 | reactive cutaneous fibrous lesion | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT01745133 Comparator | Jan 2013 → May 2014 | psoriasis | Leon Kircik, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01323673 Comparator | Nov 2010 → Mar 2011 | dermatitis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT01703325 Comparator | Nov 2010 → Mar 2012 | psoriasis | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT00881868 Comparator | Apr → Dec 2009 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00733954 Comparator | Aug 2007 → Apr 2008 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00437255 Comparator | Aug 2006 → Jun 2007 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00436540 Comparator | Mar 2006 → Jan 2007 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| — | NCT07240389 Comparator | Dec 2025 → Dec 2026 expected | vulvar lichen sclerosus | Milosz Pietrus | Not yet recruiting | No outcome recorded |
| — | NCT07536737 Comparator | Sep 2021 → Jan 2023 | lichen planus, oral | Medical University of Bialystok | Completed | No outcome recorded |
| — | NCT05818618 Comparator | Mar 2020 → Jul 2023 | lichen planus, oral | University of Catania | Completed | No outcome recorded |
| — | NCT03983460 Comparator | Mar 2020 → Jun 2021 | atopic eczema | Association pour la Recherche Clinique et Immunologique | Unknown | No outcome recorded |
| — | NCT03926299 Comparator | Jul 2019 → Jul 2024 | vulvar lichen sclerosus | Prof. Dr. Volker Viereck | Completed | No outcome recorded |
| — | NCT04673916 Comparator | Jun 2019 → Feb 2020 | lichen planus, oral, preneoplastic lesion | University of Messina | Completed | No outcome recorded |
| — | NCT03320460 Comparator | Nov 2018 → Nov 2020 | lichen planus, oral | University of Nove de Julho | Unknown | No outcome recorded |
| — | NCT02416531 Comparator | Jan 2015 → Aug 2016 | vulvar lichen sclerosus | Daniela de Fátima Teixeira da Silva | Completed | No outcome recorded |
| — | NCT01591785 Comparator | Jan → Aug 2012 | atopic eczema, hand dermatosis | Gary Goldenberg | Completed | No outcome recorded |
| — | NCT00189397 Background | Feb 2003 → Oct 2005 | toxic dermatosis | All India Institute of Medical Sciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 16
| Date | Issuer | Release |
|---|---|---|
| 2024-11-04 | Formosa Pharmaceuticals, Inc. | Results Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery formosapharma.com ↗
Treatment with an APP13007 eyedrop twice daily for 14 days achieved both primary endpoints by producing rapid and sustained clearance of ocular inflammation and cure of ocular pain which were clinically and statistically superior to placebo. |
| 2024-03-05 | Formosa Pharmaceuticals, Inc. | Regulatory Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery formosapharma.com ↗ |
| 2023-05-05 | Formosa Pharmaceuticals, Inc. | Regulatory Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery formosapharma.com ↗
announce the submission of a New Drug Application to the United States Food & Drug Administration (US FDA) for APP13007 |
| 2023-01-31 | Formosa Pharmaceuticals, Inc. | Results Formosa Pharmaceuticals Announce a Summary of Integrated Clinical Results for APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery formosapharma.com ↗
Formosa Pharmaceuticals, Inc. ( 6838 .TWO) report a summary of integrated clinical results for APP13007, a novel ophthalmic nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain after cataract surgery. |
| 2022-08-10 | Formosa Pharmaceuticals, Inc. | Results Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery. formosapharma.com ↗
Treatment with an APP13007 eyedrop twice daily for 14 days achieved both primary endpoints by producing rapid and sustained clearance of ocular inflammation and cure of ocular pain which were statistically (p<0.001) and clinically superior to placebo. |
| 2022-05-18 | Formosa Pharmaceuticals, Inc. | Results Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting formosapharma.com ↗
Dr. Jeffrey Levenson, Clinical Investigator, Associate Clinical Instructor of Ophthalmology at the University of Florida, and founding director of Levenson Eye Associates (Jacksonville, FL), will present data showing a statistically-significant and clinically-meaningful improvement of inflammation and pain with twice-daily APP13007 compared to matching placebo, a regimen that is being evaluated in the ongoing Phase 3 studies. |
| 2022-05-12 | Formosa Pharmaceuticals, Inc. | Results Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery formosapharma.com ↗
Treatment with an APP13007 eyedrop twice daily for 14 days met the two primary endpoints by producing rapid and sustained clearance of ocular inflammation and cure of ocular pain which were statistically and clinically superior to placebo. |
| 2020-05-01 | Alembic Pharmaceuticals Ltd. | Regulatory 19th May, 2020, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture, Aleor Dermaceuticals Limited (Aleor) has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Clobetasol Propionate Shampoo, 0.05%. |
| 2019-10-01 | Alembic Pharmaceuticals Ltd. | Regulatory 4th October, 2019, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received approval from. the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Clobetasol Propionate Spray, 0.05%. |
| 2019-01-08 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Clobetasol Propionate Lotion zyduslife.com ↗
Zydus Cadila has received the final approval from the USFDA to market Clobetasol Propionate Lotion, (US RLD - Clobex Lotion ), 0.05%. |
| 2018-11-26 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals receives tentative ANDA approval for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation) glenmarkpharma.com ↗
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux-E®1 Foam, 0.05%, of Mylan Pharmaceuticals, Inc. |
| 2018-03-26 | Lupin Limited | Regulatory Lupin receives FDA approval for generic Clobex® Spray, 0.05% lupin.com ↗
Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Clobetasol Propionate Spray, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of Galderma Laboratories, L.P.’s Clobex® Spray, 0.05%. |
| 2017-09-25 | Lupin Limited | Regulatory Lupin receives FDA approval for generic Clobex® Lotion lupin.com ↗
Mumbai: Pharma Major Lupin announced that it has received final approval for its Clobetasol Propionate Lotion, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of Galderma Laboratories, L.P.’s Clobex® Lotion, 0.05%. |
| 2012-08-09 | Perrigo Company | Regulatory Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05% perrigo.com ↗
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for clobetasol propionate shampoo, 0.05%, the generic equivalent of Clobex® Shampoo. |
| 2010-08-19 | Perrigo Company | Regulatory Perrigo Confirms Filing for Clobetasol Shampoo and Announcement of Patent Infringement Lawsuit by Galderma perrigo.com ↗
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced its filing with the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for clobetasol propionate shampoo, 0.05%, and notified Galderma, the listed patent owner. |
| 2009-12-09 | Perrigo Company | Regulatory Perrigo Confirms Filing for Generic Version of Clobex® Spray and Announcement of Lawsuit by Galderma and Dermalogix perrigo.com ↗
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application for Clobetasol Propionate Topical Spray, 0.05%, a generic form of Clobex® Spray. |
All press releases naming this drug 35 releases
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 84 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | clobetasol propionate | “From D0-D28 a dose of cream (Clobetasol Propionate 0.05%) will be applied twice a day for 2 weeks then once a day for 2 weeks on painful joints with the maximum dose being the...” NCT07812701 ↗79“In a study of 1254 subjects treated with clobetasol propionate spray 0.05% as monotherapy twice daily for four weeks, 35.7% of patients achieved clearance and 37.3% of patients...” NCT01012713 ↗ “The primary objective of this study was to compare the therapeutic efficacy of clobetasol propionate 0.05% oral gel versus an anti-inflammatory mouthwash in an oral solution...” NCT04673916 ↗ “the patients will be randomly treated with azathioprine 300 mg per week or azathioprine 100 mg a day orally along with topical clobetasol propionate 0.05% w/w and oral...” NCT00189397 ↗ “Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05%...” NCT03983460 ↗ “The test shampoo, Clobetasol propionate Shampoo 0.05% (marketed in the USA under the tradename of Clobex®) was developed to provide the strongest available corticosteroid as a...” NCT00438399 ↗ “Clobetasol propionate 0.05% (Clobederm) is applied topically to oral lichen planus lesions twice daily for a period of 5 weeks, according to standard clinical practice.” NCT07536737 ↗ “DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis” NCT02131324 ↗ “A Double Blind Phase II Study Comparing Safety and Efficacy of Tacrolimus Versus Topical Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus.” NCT00757874 ↗ “This study is being conducted to obtain efficacy and tolerability data for two clobetasol propionate therapies in the treatment of plaque-type psoriasis.” NCT00852761 ↗ “Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%” NCT01893567 ↗ |
| Known as | Clobederm | “Clobetasol propionate 0.05% (Clobederm) is applied topically to oral lichen planus lesions twice daily for a period of 5 weeks, according to standard clinical practice.” NCT07536737 ↗ |
| Known as | clobetasol | “OBJECTIVE: To assess the effect of clobetasol propionate ophthalmic nanoemulsion, 0.05% (clobetasol) on ocular inflammation and eye pain associated with cataract surgery.” PMID 42192627 ↗ May 20261“Clobetasol, a high-potency corticosteroid, has been shown to significantly reduce the severity of HFSR when used preemptively rather than reactively.” NCT06856590 ↗ |
| Known as | Clobetasol 17-propionate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05706870 ↗ |
| Known as | Clobex | “The test shampoo, Clobetasol propionate Shampoo 0.05% (marketed in the USA under the tradename of Clobex®) was developed to provide the strongest available corticosteroid as a...” NCT00438399 ↗2“Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%” NCT01893567 ↗ “Vectical™ (Calcitriol) Ointment 3 µg/g and Clobex® (Clobetasol Propionate) Spray, 0.05%” NCT00988637 ↗ |
| Known as | Clobex Shampoo | “Clobex® shampoo (Clobetasol Propionate) 0.05 percent (%) weight by weight (W/W) topically to the scalp once daily (twice a week) for 4 weeks” NCT00400725 ↗ |
| Known as | Clobex TM | “To determine the dose-response relationship for Clobex TM (clobetasol propionate) Lotion, 0.05%.” NCT00864240 ↗ |
| Known as | CPN | “To evaluate clobetasol propionate ophthalmic suspension (CPN) as treatment for inflammation and pain after cataract surgery.” PMID 41329923 ↗ May 2026 |
| Known as | Dermoval | “Clobetasol propionate (Dermoval® 0,05% cream), administered for 6 months.” NCT03926377 ↗1“Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream” NCT02973776 ↗ |
| Known as | Dermoval 0.05% cream | “Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05%...” NCT03983460 ↗ |
| Known as | Dermovate | “Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.” NCT01567215 ↗3“Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream” NCT02973776 ↗ “Clobetasol Propionate 0.05% Cream (Dermovate)” NCT07240389 ↗ |
| Known as | Dermovate cream | “Clobetasol propionate 0.05%(Dermovate cream) in orabase” NCT03878771 ↗ |
| Known as | Olux-E | “Clobetasol propionate foam 0.05% (Olux-E), a Class 1 corticosteroid, is formulated in an ethanol free petrolatum base that provides the benefits of a super-potent...” NCT01323673 ↗1“Olux-E (clobetasol propionate 0.05%) foam.” NCT00852761 ↗ |
| Known as | Propionate clobetasol | “Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days.” NCT03320460 ↗ |
| Known as | Rivelin-CLO patches | “Randomized, double-blind, placebo-controlled, parallel group clinical study with 3 active dose arms (Rivelin®-CLO patches) and one placebo arm (Rivelin® plain patch).” NCT03592342 ↗ |
| Action | Inhibit | “This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.” NCT03779360 ↗ |
| Modality | Small molecule | “two different forms of a topical steroid (clobetasol propionate)” NCT00852761 ↗ |
| Route | Topical | “topical clobetasol propionate 0.05% w/w” NCT00189397 ↗ |